This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (RDEA3170 + febuxostat + dapagliflozin/placebo) and follow-up visit